Sector ratings Amgen Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 06/02/2026 GMT			5-day change	1st Jan Change
384.32 ^USD	+4.49%		+12.41%	+17.42%

02-06	Guggenheim Adjusts Price Target on Amgen to $347 From $305, Maintains Neutral Rating	MT
02-06	Argus Research Adjusts Price Target on Amgen to $400 From $360, Maintains Buy Rating	MT

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
AMGEN INC.	207B		A
ELI LILLY AND COMPANY	947B		A
JOHNSON & JOHNSON	578B		BBB
ABBVIE INC.	395B		AA
ROCHE HOLDING AG	367B		AA
MERCK & CO., INC.	303B		A
ASTRAZENECA PLC	298B		A
NOVARTIS AG	295B		AAA
NOVO NORDISK A/S	208B		A
GILEAD SCIENCES, INC.	189B		AAA
PFIZER INC.	155B		BBB
BRISTOL-MYERS SQUIBB COMPANY	126B		A
VERTEX PHARMACEUTICALS INCORPORATED	121B		AA
GSK PLC	120B		AA
SANOFI	115B		A
CHUGAI PHARMACEUTICAL CO., LTD.	90.23B		AA
ALLERGAN PLC	63.66B	-	-	-	-	-	-	-
TAKEDA PHARMACEUTICAL COMPANY LIMITED	55.51B		AA
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	54.8B		AA
BAYER AG	53.15B		AA
Average	237.04B		AA
Weighted average by Cap.			AA